Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.

Palavra F, Robalo C, Reis F.

Oxid Med Cell Longev. 2017;2017:9820181. doi: 10.1155/2017/9820181. Epub 2017 Mar 12. Review.

2.

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex.

Ji S, Lin W, Wang L, Ni Z, Jin F, Zha X, Fei G.

J Cancer. 2017 Feb 11;8(4):555-562. doi: 10.7150/jca.17205. eCollection 2017.

3.
4.

PPARG is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target.

Pleniceanu O, Shukrun R, Omer D, Vax E, Kanter I, Dziedzic K, Pode-Shakked N, Mark-Daniei M, Pri-Chen S, Gnatek Y, Alfandary H, Varda-Bloom N, Bar-Lev DD, Bollag N, Shtainfeld R, Armon L, Urbach A, Kalisky T, Nagler A, Harari-Steinberg O, Arbiser JL, Dekel B.

EMBO Mol Med. 2017 Apr;9(4):508-530. doi: 10.15252/emmm.201506111.

5.

Pelvic lymphangioleiomyomatosis treated successfully with everolimus: Two case reports with literature review.

Wahid S, Chiang PC, Luo HL, Huang SC, Tsai EM, Chiang PH.

Medicine (Baltimore). 2017 Mar;96(10):e4562. doi: 10.1097/MD.0000000000004562. Review.

6.

Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation.

Cui Y, Steagall WK, Lamattina AM, Pacheco-Rodriguez G, Stylianou M, Kidambi P, Stump B, Golzarri F, Rosas IO, Priolo C, Henske EP, Moss J, El-Chemaly S.

Cancer Res. 2017 Mar 15;77(6):1492-1502. doi: 10.1158/0008-5472.CAN-16-2755. Epub 2017 Feb 15.

PMID:
28202529
7.

Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide.

Davies M, Saxena A, Kingswood JC.

Orphanet J Rare Dis. 2017 Feb 15;12(1):35. doi: 10.1186/s13023-017-0581-9. Review.

8.

Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2+/- Mice Is Superior to Everolimus Alone.

Yang J, Samsel PA, Narov K, Jones A, Gallacher D, Gallacher J, Sampson JR, Shen MH.

Neoplasia. 2017 Feb;19(2):112-120. doi: 10.1016/j.neo.2016.12.008. Epub 2017 Jan 13.

9.

Hereditary syndromes predisposing to endocrine tumors and their skin manifestations.

Stratakis CA.

Rev Endocr Metab Disord. 2016 Sep;17(3):381-388. Review.

PMID:
27943006
10.

Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review.

Bissler JJ, Kingswood JC.

Ther Adv Urol. 2016 Aug;8(4):279-290. Epub 2016 Apr 6. Review.

11.

Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.

Cao J, Tyburczy ME, Moss J, Darling TN, Widlund HR, Kwiatkowski DJ.

J Clin Invest. 2017 Jan 3;127(1):349-364. doi: 10.1172/JCI84262. Epub 2016 Dec 5.

12.

Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.

Hino O, Kobayashi T.

Cancer Sci. 2017 Jan;108(1):5-11. doi: 10.1111/cas.13116. Epub 2017 Jan 23. Review.

13.

Perivascular epithelioid cell tumor of the descending colon mimicking a gastrointestinal stromal tumor: a case report.

Iwamoto R, Kataoka TR, Furuhata A, Ono K, Hirota S, Kawada K, Sakai Y, Haga H.

World J Surg Oncol. 2016 Nov 14;14(1):285.

14.

Long-term treatment of epilepsy with everolimus in tuberous sclerosis.

Krueger DA, Wilfong AA, Mays M, Talley CM, Agricola K, Tudor C, Capal J, Holland-Bouley K, Franz DN.

Neurology. 2016 Dec 6;87(23):2408-2415. Epub 2016 Nov 4.

PMID:
27815402
15.

Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.

Samueli S, Abraham K, Dressler A, Gröppel G, Mühlebner-Fahrngruber A, Scholl T, Kasprian G, Laccone F, Feucht M.

Orphanet J Rare Dis. 2016 Nov 3;11(1):145.

16.

Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?

Habib SL, Al-Obaidi NY, Nowacki M, Pietkun K, Zegarska B, Kloskowski T, Zegarski W, Drewa T, Medina EA, Zhao Z, Liang S.

J Cancer. 2016 Jul 21;7(12):1621-1631. eCollection 2016. Review.

17.

Emerging role of mTOR in the response to cancer therapeutics.

Ilagan E, Manning BD.

Trends Cancer. 2016 May;2(5):241-251.

18.

The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.

Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA.

Eur Urol. 2017 Feb;71(2):237-246. doi: 10.1016/j.eururo.2016.08.024. Epub 2016 Aug 25. Review.

PMID:
27567210
19.

Coexistence of pulmonary lymphangioleiomyomatosis and pulmonary angiomyolipoma.

Sun X, Feng R, Zhang Y, Shi J, Xu KF.

BMC Pulm Med. 2016 Aug 15;16(1):120. doi: 10.1186/s12890-016-0286-1.

20.

Tuberous Sclerosis and Bilateral Renal Angiomyolipomas: A Case Report and Literature Review of Emerging Treatment Strategies.

Jo-Hoy F, Tolaymat O, Kunjal R, James LR.

Case Rep Nephrol. 2016;2016:4595014. doi: 10.1155/2016/4595014. Epub 2016 Jul 25.

Supplemental Content

Support Center